Caplight Raises 6M as Private Biotech Secondary Market Infrastructure Matures

A BlackRock-led $16 million Series A for a company most people have never heard of. That is not a large round by 2026 standards. Not when OpenAI raises in the billions. But Caplight is not building a model. It is building market infrastructure for a $12 trillion asset class that outgrew its trading rails three years ago.

The venture capital industry has done something unusual over the last three years: it tripled in size without the market infrastructure to support that growth. The number of private companies with venture backing now exceeds 50,000 globally. The platform tracks every one of them: funding history, cap table data, investor profiles, secondary pricing, employee growth, product launches, and customer wins. The scale is 100,000 company and investor profiles, $4 trillion in tracked funding rounds, and customers who collectively manage over $52 trillion in assets.

What secondary infrastructure actually means

The secondary market for private company shares has existed for years: broker desks, matchbooks, SPVs, one-off bilateral deals. But it was fragmented, opaque, and expensive. A fund manager wanting to price a basket of pre-IPO tech companies had to call three brokers, wait for indications, and triangulate. Pricing data was siloed inside the few firms that could afford dedicated secondary teams.

It changes that by doing three things on one platform. First, it aggregates pricing data from funding rounds, closed secondary trades, live bids and offers, and fund marks, then runs it through a patented model (US Patent No. 12,243,130) to produce daily price points on actively traded names. Second, it surfaces deal flow: $5+ billion in live buy and sell indications from the largest network of institutional brokers and counterparties. Third, it provides company intelligence: 14 signal types across funding events, talent moves, product launches, and commercial wins, refreshed continuously.

The result is the closest thing private markets have to a Bloomberg terminal: an institutional-grade data and execution layer for an asset class that, until now, operated on handshake economics.

Why now: three forces converged

Three structural shifts explain why the Series A matters beyond the company itself.

The IPO window stayed narrow. After the 2021 peak, public listings never fully reopened. Private companies that would have gone public in a normal cycle remained private longer. The 28 companies on Limen Markets' platform have a median age of eleven years. More private companies means more shares that need to change hands before a liquidity event.

Limited partners want liquidity. Pension funds and endowments that committed capital to venture funds in 2019–2021 are now sitting on mark-to-paper returns they cannot realize. Secondary sales — selling fund stakes or direct positions in high-conviction private names — have become the primary release valve. The company's own data shows that 44% of company-approved secondary volume in 2025 came from funds, up from 9% in 2022. That is $1 billion in fund-led volume, a 10× jump, with two-thirds arriving in institutional-sized blocks above $10 million.

Taboo turned to standard practice. A VC fund selling on the secondary market was once a signal of distress. That stigma has evaporated. Funds now routinely manage portfolios through partial secondary sales, and the question has shifted from "should we sell?" to "how much, and at what price?"

Biotech secondary markets: the missing link

Of the 491 biotech and pharma companies tracked on competing platform Forge Global, most are pre-revenue, pre-profit, and years from a liquidity event. Biotech has the longest time-to-exit of any venture-backed sector. A drug candidate takes a decade from IND filing to approval, with clinical trial failure rates above 90% at Phase 1. That timeline creates a structural secondary market demand that other sectors do not share.

It tracks dozens of biotech companies on its platform: ParcelBio ($14M seed), Converge Bio ($25M Series A), Leman Biotech ($28M Series A extension), and others, providing the same pricing and deal-flow infrastructure that institutional investors use for SpaceX, OpenAI, and Anduril. For a sector where information asymmetry between insiders and outside investors is extreme, having transparent secondary pricing changes the due diligence equation.

It also serves a different buyer profile for biotech. Family offices writing $1M–$25M checks are now the largest buyer cohort in late-stage secondaries overall, but for biotech specifically, crossover funds and dedicated secondary funds (Industry Ventures, StepStone, Hamilton Lane) dominate because the science requires specialist analysis that most family offices cannot sustain in-house. The company's platform narrows this gap by surfacing the same 14 signal types for biotech companies — funding rounds, senior hires, clinical trial milestones, patent filings — that it tracks for tech companies, making sector-specific due diligence more accessible to a broader investor base.

What this means for institutional allocators

The Series A signals a broader thesis: private secondary market infrastructure will become a standard part of institutional portfolio management, the way Bloomberg terminals, FactSet, and Aladdin became standard for public markets.

BlackRock's participation is the signal to watch. The world's largest asset manager does not invest $16 million in a secondary data startup for the financial return. It invests to integrate Caplight's data into Aladdin, its portfolio management platform, and to give its clients visibility into a $12 trillion asset class that most of them currently price by rumor. The strategic partnership with UBS, which joined the round as both investor and partner, reinforces this: investment banks need secondary market data to serve their private-wealth clients who increasingly want pre-IPO exposure.

The immediate implications for allocators are concrete. Better pricing data reduces the bid-ask spread that funds pay when buying or selling private company shares. Real-time signal tracking replaces the quarterly email from a GP with continuous updates on portfolio company health. And a centralized secondary marketplace means funds can execute trades in days rather than months, matching the cadence of institutional portfolio rebalancing rather than the ad-hoc rhythm of the broker-phone era.

What happens to private market infrastructure a year from now?

Development scenarios